Chronic neuroblastoma
Authors:
- Brian H. KushnerBKBrian H. Kushner
- Nai-Kong V. CheungNCNai-Kong V. Cheung
Open Access
Abstract
BACKGROUND An indolent course is associated with neuroblastoma (NB) in adolescents and adults. In the current study, the authors analyzed this phenomenon in a large series of children with metastatic NB. METHODS The authors studied 38 patients who were diagnosed with NB in the first decade of life and had metastatic disease 5 years or more from diagnosis. RESULTS The median age at diagnosis was 3 years 10 months. MYCN was amplified in 2 of 28 patients tested. Of 30 patients with classic Stage 4 NB, 9 had a late first recurrence of disease (4.3–13 years from diagnosis). Of eight patients who had atypical cases at diagnosis (one isolated mandibular lesion, two Stage 4‐N, five non‐Stage 4), six had a late first distant recurrence of disease (4 years 11 months–38 years 8 months). Nineteen patients were off therapy continuously for 3 years or more before disease recurred a first or second time. Myeloablative therapy was used to consolidate a first or second response in 27 patients. High‐dose conventional therapy helped to achieve a second remission of disease in 9 of 20 patients assessable for response of first recurrence but achieved no major responses of second or third relapse in 10 of 11 patients. The combination of anti‐GD2 immunotherapy and/or cis‐retinoic acid, targeted radiotherapy, and multiple cycles of chemotherapy with modest toxicity helped prolong survival. Twelve patients survive at 5 years 6 months+ to 19 years 4 months+ from diagnosis (median, 6 years 10 months+), including four with complete remission of disease; 10 received anti‐GD2 immunotherapy after recurrence. The other 26 patients died of disease (n = 22) or toxicity (n = 4) at 5 years–41 years 5 months from diagnosis (median, 6 years 5 months). CONCLUSIONS The concept of indolent or smoldering NB should not be limited to adolescents/adults. The expanding repertoire of anti‐NB treatments, including biologic therapies and chemotherapy regimens of modest toxicity, can convert childhood NB into a chronic disease with prolonged survival after recurrence. Cancer 2002;95:1366–75. © 2002 American Cancer Society. DOI 10.1002/cncr.10800Keywords
This publication has 44 references indexed in Scilit:
- Late relapse and prognosis for neuroblastoma patients surviving 5 years or more: A report from the European Neuroblastoma Study Group ?Survey?Medical and Pediatric Oncology, 2001
- Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic AcidNew England Journal of Medicine, 1999
- Neuroblastoma in adults and adolescentsCancer, 1997
- Long-term Survival in Refractory Recurrent NeuroblastomaJournal of Pediatric Hematology/Oncology, 1996
- Indolent course of advanced neuroblastoma in children older than 6 years at diagnosisCancer, 1995
- Serum Lactate Dehydrogenase in Childhood Neuroblastoma A Pediatric Oncology Group Recursive Partitioning StudyAmerican Journal of Clinical Oncology, 1992
- Late Recurrence of Neuroblastoma: A Report of Five Cases and Review of the LiteraturePediatric Hematology and Oncology, 1990
- Multiagent chemotherapy for children with metastatic neuroblastoma: A report from childrens cancer study groupMedical and Pediatric Oncology, 1979
- Recrudescence of Neuroblastoma After Apparent Cure12JNCI: Journal of the National Cancer Institute, 1976
- Osseous metastases in neuroblastoma.A 17-year survivalCancer, 1970